Role of lipoxygenases and the lipoxin A4/annexin 1 receptor in ischemia-reperfusion-induced gastric mucosal damage in rats

Pharmacology

Volumn 84, Issue 5, 2009, Pages 294-299

  Peskar, Brigitta M ^a   Ehrlich, Karlheinz ^a   Schuligoi, Rufina ^b   Peskar, Bernhard A ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cyclooxygenases; Gastric mucosal damage; Ischemia reperfusion; Lipoxin A 4 annexin 1 receptor; Lipoxygenases

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6,11 DIHYDRO 5 THIA 11 AZABENZO[A]FLUORENE; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; BAICALEIN; CELECOXIB; DEXAMETHASONE; FORMYLPEPTIDE RECEPTOR LIKE 1; INDOMETACIN; LIPOXIN A; LIPOXIN RECEPTOR; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; N [1 (4 BENZYLOXYPHENYL)ETHYL]ACETOHYDROXAMIC ACID; N TERT BUTOXYCARBONYLMETHIONYLLEUCYLPHENYLALANINE; PD 146176; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; ISCHEMIA; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REPERFUSION INJURY; STOMACH MUCOSA; STOMACH PROTECTION;

16,16-DIMETHYLPROSTAGLANDIN E2; ACETAMIDES; ANIMALS; ANNEXINS; ANTI-ULCER AGENTS; CYCLOOXYGENASE INHIBITORS; DEXAMETHASONE; DRUG SYNERGISM; FLAVANONES; FLUORENES; GASTRIC MUCOSA; GLUCOCORTICOIDS; INDOLES; INDOMETHACIN; LIPOXYGENASE; LIPOXYGENASE INHIBITORS; MALE; OLIGOPEPTIDES; PROSTAGLANDIN ANTAGONISTS; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; REPERFUSION INJURY; SULFONAMIDES;

EID: 70349799480     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000244017     Document Type: Article

References (17)

1. Burke A, Smyth E, Fitzgerald GA: Analgesicantipyretic and anti-inflammatory agents; pharmaocotherapy of gout; in Brunton LL, Lazo JS, Parker KL (eds): Goodman and Gilman's Pharmacological Basis of Therapeutics, ed 11. New York, McGraw-Hill, 2006, pp 671-715.
2. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar BM: Selective cyclooxygenase- 2 inhibitors aggravate ischaemiareperfusion injury in the rat stomach. Br J Pharmacol 1999; 128: 1659-1666.
3. Whittle BJ, Oren-Wolman N, Guth PH: Gastric vasoconstrictor actions of leukotriene C 4, PGF 2alpha and thromboxane mimetic U- 46619 on rat submucosal microcirculation in vivo. Am J Physiol Gastrointest Liver Physiol 1985; 248:G580-G586.
4. Fiorucci S, de Lima OM Jr, Mencarelli A, Palazzetti B, Distrutti E, McKnight W, Dicay M, Ma L, Romano M, Morelli A, Wallace JL: Cyclooxygenase-2 derived lipoxin A 4 increases gastric resistance to aspirin-induced damage. Gastroenterology 2002; 123: 1598-1606.
5. Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Foster A, Fortin R, Leger S, Mc- Farlane CS, Morton H, Piechuta H, Riendeau D, Rouzer CA, Rokach J, Young R, MacIntyre E, Peterson L, Eirmann G, Hopple S, Hupe L, Meurer R, Opas E, Pacholok S: L-663536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butylthio- 5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1989; 67: 456-464.
6. Anderson KM, Harris JE: 5,8,11,14-Eicosatretraenoic acid inhibits PC3 DNA synthesis and cellular proliferation, in part due to its 5-lipoxygenase activity. Clin Physiol Biochem 1990; 8: 308-313.
7. Sekiya K, Okuda H: Selective inhibition of platelet lipoxygenase by baicalein. Biochem Biophys Res Commun 1982; 105: 1090-1095. (Pubitemid 13219433)
8. Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, Colbry N, Dyer RD, Feinmark SJ, Daugherty A: Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol 1997; 120: 1199-1206.
9. Zanardo RC, Perretti M, Wallace JL: Annexin- 1 is an endogenous gastroprotective factor against indomethacin-induced damage. Am J Physiol Gastrointest Liver Physiol 2005; 288:G481-G486.
10. John CD, Sahni V, Mehet D, Morris JF, Christian HC, Perretti M, Flower RJ, Solito E, Buckingham JC: Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A 1, lipoxins, and bacterial peptides. FASEB J 2007; 21: 1037-1046.
11. Stroff T, Plate S, Ebrahim JS, Ehrlich K, Respondek M, Peskar BM: Tachykinin-induced increase in gastric mucosal resistance: role of afferent neurons, CGRP and NO. Am J Physiol Gastrointest Liver Physiol 1996; 271: G1017-G1027. (Pubitemid 27034376)
12. Fierro IM, Serhan CN: Mechanisms in antiinflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Braz J Med Biol Res 2001; 34: 555-566.
13. Perretti M, Chiang N, La M, Fierro IM, Marullo S, Getting SJ, Solito E, Serhan CN: Endogenous lipid- and peptide-derived antiinflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A 4 receptor. Nat Med 2002; 8: 1296-1302.
14. Gavins FN, Yona S, Kamal AM, Flower RJ, Perretti M: Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related antiinlammatory mechanisms. Blood 2003; 101: 4140-4147.
15. Trautmann M, Peskar BM, Peskar BA: Aspirin- like drugs, ethanol-induced rat gastric injury and mucosal eicosanoid release. Eur J Pharmacol 1991; 201: 53-58.
16. Chiang N, Gronert K, Clish CB, O'Brien JA, Freeman MW, Serhan CN: Leukotriene B 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999; 104: 309-316.
17. Martin GR, Perretti M, Flower RJ, Wallace JL: Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol 2008; 294:G764-G769.